FOSTER, David C.,GIEBEL, Lutz B.,PRESTA, Leonard G.
申请号：
AU2018281337
公开号：
AU2018281337A1
申请日:
2018.06.05
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
